The Latest Type 1 Diabetes Industry Statistics Explained
The global Type 1 Diabetes Market size was valued at USD 25.52 billion in 2019.
The statistic stating that the global Type 1 Diabetes Market size was valued at USD 25.52 billion in 2019 indicates the total monetary value of goods and services related to Type 1 diabetes treatment and management in that year. This figure provides insight into the economic significance of the Type 1 diabetes market on a global scale, highlighting the substantial financial resources allocated towards research, development, and consumption of products and services aimed at addressing the needs of individuals with Type 1 diabetes. Understanding the market size can help stakeholders such as healthcare providers, policymakers, and investors make informed decisions related to the advancement and accessibility of treatments for Type 1 diabetes.
This industry is projected to reach USD 25.88 billion by 2027, with a CAGR of 3.0% between 2020 and 2027.
This statistic indicates that the industry under consideration is expected to grow steadily over the forecast period, with projected revenue reaching USD 25.88 billion by 2027. The Compound Annual Growth Rate (CAGR) of 3.0% between 2020 and 2027 signifies the annual average growth rate of the industry during this period. A CAGR of 3.0% implies a moderate but consistent growth trajectory over the years, indicating a positive outlook for the industry’s future performance. This information is valuable for investors, stakeholders, and decision-makers in understanding the expected growth potential and making informed strategic decisions related to investments and market positioning within this industry.
In 2020, the U.S. accounted for the highest share in the global market, at 45%.
The statistic “In 2020, the U.S. accounted for the highest share in the global market, at 45%” indicates that within the context of worldwide market activity, the United States played a significant role by capturing 45% of the total market. This suggests that the U.S. economy had a substantial impact on the global market landscape compared to other countries or regions. Such a high market share implies that the U.S. was a major player in various industries or sectors, influencing international trade, investment, and overall economic dynamics. This statistic underscores the prominent position of the United States in the global marketplace during the specified time period.
The insulin therapy segment accounted for the highest share of 70.7% in 2020.
The statistic “The insulin therapy segment accounted for the highest share of 70.7% in 2020” indicates that among all the categories or segments within the healthcare market in 2020, insulin therapy had the largest proportion of usage or sales, capturing 70.7% of the total market. This suggests that insulin therapy was the most widely used or prescribed treatment method within the healthcare sector during that year. The high percentage indicates the significance and dominance of insulin therapy in addressing medical conditions such as diabetes, highlighting its importance in the overall healthcare landscape for that specific time period.
North America dominated the Type 1 Diabetes Market in 2019, with a revenue of USD 11.29 billion
The statistic indicates that North America was the leading region in the Type 1 Diabetes market in 2019, generating the highest revenue of USD 11.29 billion compared to other regions. This dominance suggests that there is a significant market presence and demand for Type 1 Diabetes-related products and services in North America. The high revenue figure also signifies that businesses operating in the Type 1 Diabetes market in North America were able to effectively capture market share and generate substantial income from this sector during that year. This statistic underscores the economic importance and market potential of addressing Type 1 Diabetes within the North American region.
The prevalence of Type 1 Diabetes in children aged 0-14 is approximately 1 million globally.
The statistic stating that the prevalence of Type 1 Diabetes in children aged 0-14 is approximately 1 million globally indicates the estimated number of children in that age group who have been diagnosed with Type 1 Diabetes. This statistic highlights the significant impact of this chronic condition on children worldwide, indicating that approximately 1 million children are currently managing the disease. This information underscores the public health importance of Type 1 Diabetes in children and emphasizes the need for continued research, awareness, and access to healthcare services to support those living with the condition and work towards better management and potentially a cure.
27% of Type 1 Diabetes treatment market is held by Eli Lilly Company.
The statistic ‘27% of the Type 1 Diabetes treatment market is held by the Eli Lilly Company’ indicates that Eli Lilly Company holds a significant share of the market for products related to treating Type 1 Diabetes. This suggests that a notable portion of individuals with Type 1 Diabetes use products manufactured by Eli Lilly Company for managing their condition. The statistic highlights the company’s strong presence and success within this specific market segment, which could be reflective of the effectiveness and popularity of their products among patients and healthcare providers.
Europe Type 1 Diabetes Market size was estimated to be USD 4.4 billion in 2019.
The statistic indicates that the market size for Type 1 Diabetes in Europe was estimated to be USD 4.4 billion in the year 2019. This figure represents the total value of products and services related to the treatment and management of Type 1 Diabetes within the European market during that specific year. The market size measurement serves as a key indicator of the economic significance and impact of Type 1 Diabetes in Europe, providing insights into the size and potential growth of the market, as well as informing industry stakeholders, policymakers, and healthcare professionals about the investment and revenue opportunities related to the disease.
Insulin pens accounted for nearly 40% market share in 2020.
The statistic that insulin pens accounted for nearly 40% market share in 2020 indicates that out of all the methods of insulin delivery available in the market, insulin pens were the preferred choice for approximately 40% of the users during that year. This suggests that insulin pens were widely adopted by individuals requiring insulin therapy compared to other delivery methods such as syringes or insulin pumps. The high market share of insulin pens could be attributed to several factors, including the convenience, ease of use, and discreetness of using pens for insulin administration, leading to their popularity among patients with diabetes. Overall, this statistic highlights the significant impact and prevalence of insulin pens as a preferred method of insulin delivery in the healthcare market in 2020.
The rising incidence of Type 1 diabetes in Asia Pacific is projected to register a CAGR of 3.7% by 2025.
The statistic indicates that the number of new cases of Type 1 diabetes in the Asia Pacific region is expected to increase at a compound annual growth rate (CAGR) of 3.7% by the year 2025. This suggests a steady rise in the incidence of Type 1 diabetes in the region over the specified time frame. The projection underscores the growing public health concern surrounding diabetes in Asia Pacific, potentially reflecting factors such as changing lifestyles, dietary habits, and genetic predispositions leading to an increased risk of developing Type 1 diabetes. The data highlights the need for proactive measures and interventions to address the rising prevalence of Type 1 diabetes in the Asia Pacific region.
The cost of Type 1 Diabetes management in the US can be more than $2,500 a patient each month.
The statistic that the cost of Type 1 Diabetes management in the US can exceed $2,500 per patient each month reflects the financial burden associated with the treatment and care of this chronic condition. Managing Type 1 Diabetes requires regular monitoring, specialized medical equipment, medication, healthcare provider visits, and potential complications management, all of which contribute to the high monthly cost. The significant financial cost underscores the importance of access to affordable healthcare, insurance coverage, and support services for individuals living with Type 1 Diabetes to ensure they can effectively manage their condition and maintain their health and quality of life.
By 2024, Type 1 Diabetes Drugs Market in Asia is projected to reach USD 5.01 Billion.
The statistic “By 2024, Type 1 Diabetes Drugs Market in Asia is projected to reach USD 5.01 Billion” indicates the estimated value of the market specifically for drugs used in the treatment of Type 1 Diabetes in Asia by the year 2024. This projected worth of USD 5.01 billion suggests a significant market size and potential growth in the region with regards to pharmaceutical products for managing Type 1 Diabetes. Factors contributing to this projection may include increasing prevalence of Type 1 Diabetes, rising awareness and diagnosis rates, advancements in drug development, and potentially expanding access to healthcare services in Asian countries. This statistic serves as a valuable insight for stakeholders in the healthcare and pharmaceutical industries to forecast market trends, investment opportunities, and regulatory considerations related to Type 1 Diabetes drugs in the Asian region.
The Continuous Glucose Monitoring Systems market is expected to grow at a CAGR of 12.7% from 2019 to 2027.
This statistic indicates that the Continuous Glucose Monitoring Systems market is projected to experience a steady growth rate over the period from 2019 to 2027, with a Compound Annual Growth Rate (CAGR) of 12.7%. This means that on average, the market is expected to increase by 12.7% each year during this time frame. Such a notable growth rate suggests a growing demand for continuous glucose monitoring systems, likely driven by factors such as advancements in technology, increasing prevalence of diabetes, and rising awareness about the importance of continuous glucose monitoring for managing blood sugar levels effectively. This forecasted growth trajectory indicates a promising outlook for the Continuous Glucose Monitoring Systems market in the coming years.
Insulin pumps contributed to over 20% market share in the Europe Diabetes Care Devices Market in 2019.
The statistic implies that insulin pumps held a significant portion of the market in the Europe Diabetes Care Devices Market in 2019, accounting for over 20% of the total market share. This suggests that insulin pumps were a popular and widely used option for managing diabetes among individuals in Europe during that period. The high market share indicates that there was a substantial demand for insulin pumps as a method of insulin delivery for diabetes management, potentially due to benefits such as improved convenience, better glucose control, and enhanced quality of life for diabetes patients in the region.
US insulin pumps and accessories market size was valued at $1.3 billion in 2020.
The statistic states that the market size for insulin pumps and accessories in the United States was estimated to be $1.3 billion in the year 2020. This figure represents the total value of all sales within this specific market segment during that year. It indicates the significant demand for insulin pumps and related accessories in the US, reflecting the reliance on these medical devices by individuals with diabetes to manage their condition effectively. The market size of $1.3 billion underscores the economic importance of this sector within the healthcare industry and highlights the ongoing need for innovative products and solutions to support individuals living with diabetes in the country.
The global market for insulin biosimilars is set to grow with a CAGR of 19.2% by 2025.
This statistic indicates that the global market for insulin biosimilars is expected to experience a Compound Annual Growth Rate (CAGR) of 19.2% by the year 2025. A high CAGR suggests rapid growth in market demand for these lower-cost alternatives to branded insulin products. This projection implies that there is a growing trend towards the adoption of insulin biosimilars, likely driven by factors such as increasing prevalence of diabetes, efforts to reduce healthcare costs, and advancements in biotechnology. As a result, companies manufacturing and selling insulin biosimilars may see significant opportunities for expansion and market penetration in the coming years.
The Type 1 Diabetes (T1D) Market in Japan was USD 1.96 Bn in 2020.
The statistic “The Type 1 Diabetes (T1D) Market in Japan was USD 1.96 Bn in 2020” indicates the total value of the market for products and services related to Type 1 Diabetes in Japan for the year 2020, which amounted to 1.96 billion US dollars. This figure encompasses the revenue generated from the sales of medications, devices, diagnostics, and other healthcare products specifically targeting Type 1 Diabetes within the Japanese market. The statistic highlights the economic significance and size of the T1D market in Japan, providing valuable insights for stakeholders such as pharmaceutical companies, healthcare providers, policymakers, and investors operating in the diabetes care sector.
85% of the global burden of Type 1 Diabetes is borne by low- and middle-income countries.
This statistic indicates that a substantial majority, specifically 85%, of the total impact of Type 1 Diabetes worldwide is experienced by low- and middle-income countries. This suggests that individuals living in these regions are disproportionately affected by the burden of managing and treating Type 1 Diabetes compared to those in high-income countries. Factors such as limited access to healthcare resources, affordability of medications and technology, and potentially poorer overall health infrastructure may contribute to the higher prevalence and impact of Type 1 Diabetes in these regions. Addressing this disparity in global health outcomes related to Type 1 Diabetes would likely require targeted interventions and increased support for healthcare systems in low- and middle-income countries.
References
0. – https://www.www.who.int
1. – https://www.www.transparencymarketresearch.com
2. – https://www.www.healthline.com
3. – https://www.www.marketresearch.com
4. – https://www.www.researchdive.com
5. – https://www.www.gminsights.com
6. – https://www.www.grandviewresearch.com
7. – https://www.www.pharmiweb.com
8. – https://www.www.fortunebusinessinsights.com
9. – https://www.www.marketsandmarkets.com
